Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclophosphamide and Radiation in Metastasized Breast Cancer
NCT02441270Phase 1Withdrawn
- Sponsor
- Ghent University Hospital
- Start
- Apr 2015
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cyclophosphamide in breast cancer, sponsored by Ghent University Hospital. Primary endpoint: Identification of the immunological effects at 1.5 years. Planned start Apr 2015; status: withdrawn.
02
Drugs
cyclophosphamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02441270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02441270.